Bangkok--Dec 26--Shandwick International (Thailand)
The top award in pharmaceutical research for outstanding achievement, Prix Galien, was given to the Pfizer Scientists in England for their discovery and development of the first oral medicine for the treatment of erectile dysfunction.
Since its inception in France in1970, an eminent international jury of medical researchers has awarded the Prix Galien to discoverers of breakthrough medicines. The award is the highest accolade for research and development in the biomedical industry.
"We are honoured that the Prix Galien has recognized the Pfizer Research Team for their pioneering observation of the role of an enzyme, the phosphodiesterase type 5 inhibitor (PDE5), in the treatment of erectile dysfunction," said Amal Naj, Country Manager of Pfizer Thailand.
"After winning the approval of regulatory agencies, Pfizer's PDE5 inhibitor, sildenafil citrate, quickly revolutionized the treatment of erectile dysfunction. It is important to remember, though, that sildenafil citrate was the culmination of a decade and a half of arduous, high-risk, research and development and an unwavering commitment to the needs of patients who suffer from this often under-reported and debilitating medical condition."
Erectile dysfunction (ED) is one of the most common male sexual problems, affecting more than 100 million men worldwide. It can often indicate other serious health conditions, such as diabetes, cardiovascular disease and depression.
In Thailand, the first official epidemiological study of ED was conducted recently. It involved 1,250 men from across the country. The study showed that 37.5% of respondents suffered from some degree of ED. "The study indicates that more than 3 million Thai men in the country between the ages of 40 and 70 suffer from ED", said Mr. Naj.
Professor Sir Michael Rawlins, Chair of the National Institute for Clinical Excellence, presented Pfizer with the international prize which is given for medical and scientific innovation that makes a lasting contribution to patient care. "This drug has become a household name," Sir Michael said. "It is innovative, well tolerated, and provides treatment where existing therapies have been shown to be suboptimal."
Sildenafil citrate resulted from the efforts of a research team at the Pfizer European Research Centre in Sandwich, England. A programme of extensive clinical trials investigated the role of selectively inhibiting the enzyme phosphodiesterase type 5 (PDE5), on which sildenafil citrate acts, to enhance the natural mechanism of penile erection. During sexual stimulation, the blood vessels in the penis are relaxed, allowing blood to flow to the area, resulting in an erection.
Pfizer researchers synthesized the compound in 1989 and conducted trials in more than 4400 men of different ages, backgrounds and health status, at medical centres worldwide. Clinical trial data showed that sildenafil citrate improved erections in 7 out of 10 patients.
"Sildenafil citrate has helped millions of men and their partners overcome the devastating effects of ED on their quality of life. It is now widely accepted among ED patients in Thailand," Mr. Naj said.
Pfizer Inc, discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world's best known over-the-counter brands. This year, Pfizer expects global revenues of about $30 billion and has an estimated research and development investment of US$ 4.7 billion (Bt 188 billion) in 2000.
For additional information contact:
Pongprach Surojanametakul
Shandwick International (Thailand) Limited
Tel 257 0300 Fax 257 0312 End.
-AN-